Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) announced on Monday that it has completed the safety analysis from its proof-of-concept Phase 2, randomised, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer's disease.
According to the company, the evaluation demonstrated a favourable tolerability profile for PrimeC. No serious adverse events were reported, and no new or unexpected safety signals were identified.
NeuroSense will analyse clinical observations alongside biomarker data to enable a more comprehensive interpretation of the clinical observations, with results expected in the first quarter of 2026.
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study